Omeros announced positive data from the company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program. Omeros is advancing OMS824 into Phase 2 clinical programs. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. At the highest multiple-dose level administered, OMS824 was well tolerated and the only apparent drug-related adverse events were mild. The Phase 1 clinical trial results predict that OMS824, at well-tolerated doses, will effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.